Loading...
First-In-human phase 1/2 trial of anti-AXL antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in advanced NSCLC
Ramalingam, S Lopez, J Mau-Sorensen, M Piha-Paul, S Gadgeel, S Drew, Y Janne, P Mansfield, A Chen, G
Ramalingam, S
Lopez, J
Mau-Sorensen, M
Piha-Paul, S
Gadgeel, S
Drew, Y
Janne, P
Mansfield, A
Chen, G
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ramalingam S, Lopez J, Mau-Sorensen M, Thistlethwaite F, Piha-Paul S, Gadgeel S, et al. OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC. Journal of Thoracic Oncology. 2019;14(10):S209.